Online Broadband Guide
Online Broadband Guide

FDA approves first-of-its-kind 'living drug' for childhood leukemia

FDA approves first-of-its-kind 'living drug' for childhood leukemia

The agency called the decision a "historic action" because the therapy, developed by Novartis, is the first gene therapy treatment approved in the United States.

The first cancer treatment that involves reprogramming a patient's own blood cells to fight cancer has been approved by the US Food and Drug Administration, leading the way for federal approval of other, similar efforts.

In this type of therapy, patients' own immune cells are modified ex vivo to include a gene for the vehicle protein, which directs them to attack leukemia cells carrying the CD19 antigen. It is the first gene therapy of its kind to hit the USA market.

The drug, known as Kymriah (tisagenlecleucel), will be used to treat certain pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). "New technologies such as gene and cell therapies hold out the potential to transform medicine". Based on those results, an FDA advisory panel recommended the approval in July.

The treatment is not a pill or a form of chemotherapy.

Short for chimeric antigen receptor T-cell therapy, CAR-T treatment takes a person's own cells, removes them from the body, re-engineers them, and then puts the cells back in the body where they can attack cancer cells.

The Kymriah approval came just over three months after the first patient to receive it, 12-year-old Emily Whitehead of Philipsburg, Pa., celebrated five years cancer-free in May.

The treatment, which is expected to be costly, can cause serious side effects including high fevers and neurological problems.

"Kymriah is a first-of-its-kind treatment approach that fills an important unmet need for children and young adults with this serious disease", Peter Marks, MD, PhD, direct of the Center for Biologics Evaluation and Research, FDA, said in the release. (Currently, CAR-T companies have been focusing on blood cancers.) "We also want to see if we can expand it to other diseases down the line", he said.

Novartis is also required to conduct a post-marketing observational study involving patients treated with Kymriah, to further evaluate the long-term safety of the CAR-T therapy.

The road to approval for CAR-T has been filled with uncertainty, but Novartis and lead rival Kite Pharma made strides over the previous year, notably with Novartis' recent unanimous FDA panel vote in favor of approval and Kite's $11.9 billion acquisition this week by Gilead Sciences. Made from scratch for every patient, it's one of a wave of "living drugs" under development to fight additional blood cancers and other tumors, too.

On a conference call Wednesday, Novartis executives said the company is working with the Medicaid program and private insurers and expects broad coverage and will offer some financial assistance with such things as copay and travel costs.

In a key study of 63 advanced patients, 83 percent went into remission soon after receiving the CAR-T cells.

Despite its great promise, the FDA warns that Kymriah does have the potential for severe side effects.



editors' picks

August 31, 2017
Auburn player asks for prayers for flooded hometown in Texas
Center meteorologist Dennis Feltgen said Tuesday that when Harvey came back to shore, "it's the end of the beginning". Neighbors helped bring her and 12 other people who had sought refuge in her home to a Baptist church on higher ground.

August 31, 2017
Britain's Princes William, Harry visit new memorial of Princess Diana
The Sun reported that Mansfield opened up about his doubts on the real cause of Di's death through the new documentary in the U.S. He said that the French emergency services had delayed in coming to her rescue, thereby reducing her chances of survival.

August 31, 2017
Deposed Uber chief Travis Kalanick welcomes new CEO
In November Uber had come under fire for not providing the customers with an option to track their location "while using the app". We are delighted to announce that Uber's Board has voted unanimously to appoint Dara Khosrowshahi to be our new CEO.

August 31, 2017
Federer passes five-set test to advance at US Open
So that would have been tougher for me maybe to back it up back-to-back days. Rafa Nadal starts his quest for a third US Open on 29 August 2017.

August 29, 2017
US President Donald Trump faces tough choice over border wall threats
Wall Street suffered slightly as a result of President Trump's words, with stocks heading downwards, reversing some previous gains.

August 29, 2017
United Kingdom warns European Union not to 'drag its feet' on Brexit
The EU has also accused the United Kingdom of "magical thinking" on its solutions to providing a "frictionless" border in Ireland. It wants to start talks on certain issues as soon as possible, such as the border between Ireland and Northern Ireland .

August 27, 2017
Walker-Peters extends Tottenham contract
"It's great to sign a new contract and commit my future to the club", Walker-Peters told Tottenham's official Twitter account . The club didn't announce details on KWP's new contract, but you can expect he received a healthy bump in his pay.

August 27, 2017
President Trump Pardons Former Sheriff Joe Arpaio
He had admitted to inadvertently disobeying the court order but said his behaviour did not meet a criminal standard. This would have involved an FBI background investigation on Arpaio and could have taken months or even years.

August 25, 2017
Missing Swedish Journalist Headless Torso Found At Sea
Metal had been attached to the body and had "deliberate damage" inflicted in a possible attempt to ensure it sank, police said . The inventor was charged with manslaughter on August 11 and ordered to be held in custody for 24 days.

August 25, 2017
New Quinnipiac Poll: Trump is dividing the country
Trump has popularized use of the term "fake news" to criticize news media and reporters that he contends treat him unfairly. Another 10 percent said of those surveyed said they either did not know or were not certain which option they preferred.